ICON plc ICLR
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $8.25B, +0.8% YoY · Filed May 27, 2026
ICON plc (ICLR) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $8.3 billion and net income of $229.3 million. Free cash flow was $862.0 million. As of Dec 31, 2025 it held $647.3 million in cash and investments and $3.0 billion in total debt.
Revenue
$8.25B
+0.8% vs prior year
Net income
$229.34M
-69.0% vs prior year
Operating cash flow
$1.04B
-19.5% vs prior year
Free cash flow
$861.99M
-22.9% vs prior year
EPS
$2.90
-67.4% vs prior year
Dividend per share
None
Shares outstanding
76.57M
-5.2% vs prior year
Net cash
$-2.38B
FY 2025
Operating margin
5.4%
FY 2025
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ICLR (Nasdaq)
- Headquarters
- Dublin 18, Ireland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1060955
- Former names
- ICON PLC /ADR/ (until Feb 7, 2013)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $8.3B | $8.2B | $8.1B | $7.7B | $5.5B |
| Operating income | $442.8M | $1.0B | $904.7M | $795.2M | $378.5M |
| Net income | $229.3M | $739.1M | $554.2M | $505.3M | $153.2M |
| Diluted EPS | $2.90 | $8.90 | $6.70 | $6.13 | $2.25 |
| Operating cash flow | $1.0B | $1.3B | $1.2B | $563.3M | $829.1M |
| Free cash flow | $862.0M | $1.1B | $1.0B | $421.2M | $735.4M |
| Total assets | $16.3B | $16.6B | $16.9B | $17.2B | $17.4B |
| Total liabilities | $7.1B | $7.2B | $7.7B | $8.7B | $9.3B |
| Stockholders' equity | $9.2B | $9.4B | $9.2B | $8.5B | $8.1B |
| Cash and investments | $647.3M | $538.8M | $426.9M | $323.1M | $753.9M |
| Total debt | $3.0B | $3.6B | $4.0B | $4.9B | $5.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Aug 20, 2026 | Aug 20, 2026 |
| 6-K | Current report (foreign issuer) | Aug 18, 2026 | Aug 14, 2026 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.